Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02736565 · ClinicalTrials.gov registry record · Phase 1
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
A Phase 1 study, sponsored by Gradalis.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02736565 is a Phase 1 study that has completed, run by Gradalis. The registered enrollment target is 7 participants.
The verdict
NCT02736565, a Phase 1 study, has completed, sponsored by Gradalis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and the maximum tolerated dose of of pbi-shRNA™ EWS/FLI1 Type 1 lipoplex in patients with advanced Ewing's sarcoma.
Interventions
- BIOLOGICAL pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-10 |
| Est. Completion | 2020-08-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02736565
The ClinicalTrials.gov registry entry for NCT02736565 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gradalis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex is the first listed.
NCT02736565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02736565 about?
NCT02736565 is a clinical study titled "Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma". The purpose of this study is to determine the safety and the maximum tolerated dose of of pbi-shRNA™ EWS/FLI1 Type 1 lipoplex in patients with advanced Ewing's sarcoma.
What is the current status of trial NCT02736565?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2016-10. Estimated completion is 2020-08-04.
What interventions are being tested in trial NCT02736565?
The interventions under investigation include: pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex (BIOLOGICAL).
Who is sponsoring clinical trial NCT02736565?
This trial is sponsored by Gradalis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.